The Omega-3 Index: Why This Number Matters More Than Your LDL

The Omega-3 Index measures the percentage of EPA and DHA — the two most important omega-3 fatty acids — in your red blood cell membranes. Because red blood cells turn over slowly (about every 120 days), this number reflects your actual long-term omega-3 status, not what you had for dinner. First proposed as a cardiovascular risk biomarker by Harris and von Schacky in 2004, over 450 published studies have validated its use.[1] A 2025 review confirmed it remains the most widely used and validated omega-3 status metric in clinical research.[2]

The target range is 8–11%. Below 4% is high risk. Between 4–8% is intermediate.

“Nearly 89% of the U.S. population falls into the highest-risk category. Only about 1% of adults reach the optimal range. The average Japanese citizen typically exceeds 8%.”

An NHANES-based analysis found that nearly 89% of the U.S. population falls into the highest-risk category, and only about 1% of adults reach the optimal range.[3] The average Japanese citizen typically exceeds 8% — and Japan has among the lowest rates of sudden cardiac death in the developed world.

The original Harris and von Schacky paper showed a graded, inverse relationship between the Omega-3 Index and coronary heart disease death. An index above 8% was associated with the greatest cardioprotection; at or below 4%, the least.[1]

More recent data has expanded this considerably. A pooled analysis of 17 prospective cohort studies published in Nature Communications found that higher blood omega-3 levels correlated with lower risk of dying from cardiovascular disease, cancer, and other causes.[4] A 2025 meta-analysis of 42 RCTs involving over 176,000 participants confirmed significant reductions in cardiovascular mortality, MI, fatal MI, and revascularization with omega-3 supplementation.[5] A separate 2025 systematic review found a strong inverse association between circulating omega-3 levels and sudden cardiac death specifically.[6]

That's not just heart health. That's broad-spectrum mortality reduction tied to a single modifiable biomarker.

If you've heard that fish oil “doesn't work,” you're not wrong about the headlines — but you might be wrong about the conclusion. Several large trials (VITAL, ASCEND, OMEMI) showed minimal benefit. But here's what most of those trials didn't do: they didn't check whether the supplement actually changed participants' Omega-3 Index.

The OMEGA-REMODEL trial illustrates the problem. Overall, no benefit from high-dose EPA+DHA after heart attack. But about a third of participants had a meaningful rise in their Omega-3 Index — and in that subgroup, the biology responded differently.[7] The supplement only works when it actually changes the biomarker. This is the entire argument for testing rather than guessing.

The 2025 Mattumpuram meta-analysis found EPA monotherapy significantly outperformed combination therapy across nearly every cardiovascular endpoint, though it also increased atrial fibrillation risk.[5] The clinical takeaway: the specific fatty acid composition matters, the dose matters, and testing is the only way to know if your approach is working.

The Omega-3 Index is showing up in cognitive research, inflammation science, and sports medicine. Studies have linked higher indices to better memory, faster processing speed, and larger brain volumes on MRI.[2] The Cooper Center Longitudinal Study found that an Omega-3 Index below 4% was associated with greater cognitive impairment compared to levels above 8%, even after controlling for cardiorespiratory fitness.

EPA and DHA are precursors to resolvins and protectins — molecules that don't just suppress inflammation but actively resolve it. Think of NSAIDs as hitting the mute button on a fire alarm. Resolvins are the fire department actually putting out the fire. Low omega-3 status means your body has fewer tools for cleaning up inflammatory responses — the kind that, unresolved over years, drive atherosclerosis, insulin resistance, and neurodegeneration.

Get tested. The Omega-3 Index is a dried blood spot fingerstick test — simple, cheap, and informative. If your level is below 8%, you need more EPA and DHA. The most effective approach is fatty fish three times per week combined with a quality supplement. On average, about 1,300 mg per day of combined EPA+DHA gets roughly half of people to the 8% target; 1,900 mg per day gets about 90% there. But individual response varies — so retest in 3–4 months to confirm.

Not all fish are equal. Wild salmon, sardines, mackerel, and herring are the heavy hitters. Shrimp, tilapia, and most white fish have minimal EPA and DHA. Plant-based omega-3s (flaxseed, walnuts) convert to EPA and DHA at roughly 5–10% efficiency — not enough to move the needle.

On supplements: choose products that are third-party tested (USP, NSF, or IFOS), list actual EPA and DHA content per serving (not just “fish oil”), and use triglyceride form for better absorption. A capsule labeled “1,000 mg fish oil” might only contain 300 mg of actual EPA+DHA — read the fine print.

The Omega-3 Index is a measurable, modifiable biomarker with a clear target, a clear dose-response relationship, and evidence linking it to the outcomes that actually matter. It's cheap to test. It's safe to act on. And it's almost universally ignored. Nearly 90% of Americans are walking around with omega-3 levels in the highest risk category. If you're investing proactively in your health, this number belongs on your dashboard.